17,261 trials
Multiple Myeloma
Primary: Number of Phase I Patients Receiving 2.3mg, 3mg, or 4mg MLN9708 Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Maximum Tolerated Dose — 0; 0; 0 Participants
Type 2 Diabetes · Insulin Resistance · High Insulin Requirements
Primary: Duration (in Hours) of 20 % Dextrose Infusion Requirement — 11; 16.5 hours
Myasthenia Gravis
Primary: Percent of Subjects Achieving a 50% or Greater Reduction in CS Dose (Prednisone or Equivalent) From Baseline to Week 39 — 60.0; 63.3; 58.6; 60.7 percentage of subjects…
Recurrent Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Participants With Adverse Events — 0; 15; 15 percentage of participants
Systemic Lupus Erythematosus
Primary: Change in Total Lymphocyte Count From Baseline to End-of-treatment (EOT) — -0.26; -0.96; -0.86; -0.87 10^9 cells/L — p=0.39
Recurrent Thyroid Gland Carcinoma · Stage III Differentiated Thyroid Gland Carcinoma AJCC v7 · Stage III Thyroid Gland Medullary Carcinoma AJCC v7
Primary: Overall Response Rate (in Cohorts 1-3) — 49; 14; 0 percentage of participants
Carcinoma, Squamous Cell · Adenocarcinoma of the Esophagus and Gastric Cardia
Primary: Pathological Complete Histological Response (pCR) After Resection Than Chemotherapy Alone in Patients With Resectable Carcinoma of the Esophagus and Cardia. — 22; 7…
Lupus Nephritis
Primary: Percentage of Participants Who Achieve Protocol Defined Complete Renal Response (CRR) at Week 52 — 22; 14 Participants — p=0.1145
HIV
Primary: Change in Human Immunodeficiency Virus 1 (HIV-1) Ribonucleic Acid (RNA) Levels — 0; 0; -0.03; -0.08 Log10 copies/ml plasma
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Change-from-baseline in Serum Lactate Dehydrogenase (LDH) Levels. — 100.3 U/L
Heart Failure
Primary: Number of Participants With Post-treatment Sustained Virologic Response (SVR) — 9 Participants
Infertility, Male · Depression
Primary: Number of Participants With Abnormal Sperm DNA Fragmentation at 6 Weeks — 0; 2 Participants
Ectropion · Skin Neoplasms
Primary: Graft Size Change — 10 percent change in graft
Leukemia
Primary: Maximum Tolerated Dose (MTD) of Clofarabine, Idarubicin, and Cytarabine — 15 mg/m^2
Metabolic Disease · Seizures
Primary: Change From Baseline on the Adaptive Behavior Assessment System (ABAS) Test at the End of the Study Drug and Placebo Treatment Periods — 5.2; 4.5 scores on a scale